Corporate | 21 February 2011 07:00
|
Cytos Biotechnology AG / Key word(s): Research Update
Schlieren (Zurich), Switzerland, February 21, 2011 – Cytos Biotechnology Ltd (SIX: CYTN) announced today that it has received European Union funding to work in a scientific consortium with the goal of preventing and treating infections caused by emerging viral pathogens deemed to be of threat to Europe. The consortium, known as VECTORIE, is funded by the European Commission Framework Program 7 (Grant # 261466) and will employ a multidisciplinary approach involving virology, entomology and advanced vaccinology. Cytos’ Biotechnology VLP platform has been selected to generate vaccine candidates which will be tested in disease models. Dr Martin Bachmann, CSO of Cytos Biotechnology commented ‘We are very much looking forward to participating in this exciting collaboration and potentially providing novel intervention strategies to help prepare Europe against the threat of emerging viral diseases. This program, together with our recently announced partnerships with the NIH and A*STAR in Malaria and Influenza respectively, exemplifies the broad recognition and appeal of our VLP platform technology’.
For further information please contact:
About Cytos Biotechnology
This foregoing press release may contain forward-looking statements that include words or phrases such as ‘may’, ‘will’, ‘has been selected’, ‘providing’, ‘designed’, ‘intend’ or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd. End of Corporate News 21.02.2011 News transmitted by EquityStory AG. The issuer is responsible for the contents of the release. EquityStory publishes regulatory releases, media releases on the capital market and press releases. The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies. The Swiss news archive can be found at http://www.equitystory.ch/nachrichten |
| Language: | English | |
| Company: | Cytos Biotechnology AG | |
| Wagistr. 25 | ||
| 8952 Schlieren | ||
| Schweiz | ||
| Phone: | +41 44 733 4747 | |
| Fax: | +41 44 733 4740 | |
| E-mail: | info@cytos.com | |
| Internet: | www.cytos.com | |
| ISIN: | CH0011025217, CH0029060735 | |
| Swiss Security Number: | – | |
| Listed: | Regulierter Markt in SIX; Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt | |
| End of News | EquityStory AG News-Service |
|
|
| 112724 21.02.2011 |